This free case-based activity includes a crowd-sourced discussion of 2 cases: In Case #1, a 40-year old man developed a changing mole on his left upper back which revealed a 3.5 mm thick, ulcerated nodular melanoma with 8 mitoses per square millimeter. A lymph node disssection revealed 11 additional axillayr nodes, 2 of which were microscopically involved with melanoma. In case #2, a 45 year-old man who developed a right upper arm skin lesion, which revealted a 1.75 mm thick non-ulcerated superficial spreading melanoma with no evidence of ulceration and 1 mitosis per square millimeter, later then underwent a wide excision and sentinel lymph node evaluation, which showed no evidence of residual melanoma in the excision site and no evidence of involvement of either of the two identified right axillary sentinel lymph nodes. Originally posted on a forum in the ASCO Connection, participants now have the opportunity to claim a CME, completion, or participation certificate for completing this activity.
- Evaluate treatment options for patients with selected melanoma diagnosis, considering targeted and immune therapy approaches in BRAF and NRAS mutations
- Determine the potential gene testing options available and explain why those selections are recommended and their prognostic significance
- Discuss the therapeutic management of patients with melanoma using first-line and second-line therapy and in patients with CNS metastases
Continuing Education Credit
1 Credit/Point is available for participation in this course. Certificate and credit types available include:
- AMA PRA Category 1 Credits™
- Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
- Certificate of Completion may be used to document participation, but no credit will be conferred.
- This course expires on October 30, 2018. Participants must complete all necessary course components by this date to receive credit.